OBJECTIVE: To compare the incidence of liver toxicity and clinical response between 2 initial dosing regimens of methotrexate (MTX) for treatment of juvenile idiopathic arthritis (JIA). METHODS: Clinical and laboratory data were abstracted from the medical records of 220 children newly prescribed MTX from the same geographic region. One cohort received initial doses of MTX > 0.5 mg/kg/week ("high-dose") and one cohort received initial doses of MTX <or= 0.5 mg/kg/week ("low-dose"). Toxicity was defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) above the normal range, and positive clinical response was defined as a reduction in active joint count during the first 6 months of MTX therapy. RESULTS: One hundred twenty-six children were in the high-dose MTX group, 94 in the low-dose MTX group. At 6 months, the high-dose group was more likely to have an elevated AST or ALT (adjusted OR 3.89, 95% CI 1.82-8.29, p < 0.0001). Subjects receiving both MTX and nonsteroidal antiinflammatory drugs (NSAID) had no significant difference between groups in change of active joint count, while subjects in the high-dose group but not taking NSAID had more active joints (p = 0.036) at 6 months compared to the low-dose group. CONCLUSION: Initial high-dose MTX was associated with an increased risk of at least one liver enzyme abnormality with no significant improvement in active joint count. This suggests that there is no apparent benefit, while the potential for liver toxicity is increased, when using higher doses of MTX at treatment inception in patients with JIA.
OBJECTIVE: To compare the incidence of liver toxicity and clinical response between 2 initial dosing regimens of methotrexate (MTX) for treatment of juvenile idiopathic arthritis (JIA). METHODS: Clinical and laboratory data were abstracted from the medical records of 220 children newly prescribed MTX from the same geographic region. One cohort received initial doses of MTX > 0.5 mg/kg/week ("high-dose") and one cohort received initial doses of MTX <or= 0.5 mg/kg/week ("low-dose"). Toxicity was defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) above the normal range, and positive clinical response was defined as a reduction in active joint count during the first 6 months of MTX therapy. RESULTS: One hundred twenty-six children were in the high-dose MTX group, 94 in the low-dose MTX group. At 6 months, the high-dose group was more likely to have an elevated AST or ALT (adjusted OR 3.89, 95% CI 1.82-8.29, p < 0.0001). Subjects receiving both MTX and nonsteroidal antiinflammatory drugs (NSAID) had no significant difference between groups in change of active joint count, while subjects in the high-dose group but not taking NSAID had more active joints (p = 0.036) at 6 months compared to the low-dose group. CONCLUSION: Initial high-dose MTX was associated with an increased risk of at least one liver enzyme abnormality with no significant improvement in active joint count. This suggests that there is no apparent benefit, while the potential for liver toxicity is increased, when using higher doses of MTX at treatment inception in patients with JIA.
Authors: M Speckmaier; J Findeisen; P Woo; A Hall; J A Sills; T Price; P Hollingworth; A Craft; B M Ansell Journal: Clin Exp Rheumatol Date: 1989 Nov-Dec Impact factor: 4.473
Authors: Oliva Ortiz-Alvarez; Kimberly Morishita; Glenda Avery; Jayne Green; Ross E Petty; Lori B Tucker; Peter N Malleson; David A Cabral Journal: J Rheumatol Date: 2004-12 Impact factor: 4.666
Authors: E H Giannini; E J Brewer; N Kuzmina; A Shaikov; A Maximov; I Vorontsov; C W Fink; A J Newman; J T Cassidy; L S Zemel Journal: N Engl J Med Date: 1992-04-16 Impact factor: 91.245
Authors: Nicolino Ruperto; Kevin J Murray; Valeria Gerloni; Nico Wulffraat; Sheila Knupp Feitosa de Oliveira; Fernanda Falcini; Pavla Dolezalova; Maria Alessio; Ruben Burgos-Vargas; Fabrizia Corona; Richard Vesely; Helen Foster; Joyce Davidson; Francesco Zulian; Line Asplin; Eileen Baildam; Julia Garcia Consuegra; Huri Ozdogan; Rotraud Saurenmann; Rik Joos; Angela Pistorio; Pat Woo; Alberto Martini Journal: Arthritis Rheum Date: 2004-07
Authors: Laila Holmboe; Anders M Andersen; Lars Mørkrid; Lars Slørdal; Kirsten Sundby Hall Journal: Br J Clin Pharmacol Date: 2012-01 Impact factor: 4.335
Authors: Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan Dewitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe Journal: Arthritis Care Res (Hoboken) Date: 2013-10 Impact factor: 4.794
Authors: Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe Journal: Arthritis Rheum Date: 2013-10
Authors: Gil Amarilyo; Gil Amarlilyo; Ornella J Rullo; Deborah K McCurdy; Jennifer M P Woo; Daniel E Furst Journal: Rheumatol Int Date: 2013-02-12 Impact factor: 2.631
Authors: Hongying Dai; Madhusudan Bhandary; Mara Becker; J Steven Leeder; Roger Gaedigk; Alison A Motsinger-Reif Journal: BioData Min Date: 2012-05-22 Impact factor: 2.522
Authors: Ahmed F Hawwa; AbdelQader AlBawab; Madeleine Rooney; Lucy R Wedderburn; Michael W Beresford; James C McElnay Journal: Arthritis Res Ther Date: 2015-10-22 Impact factor: 5.156